SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jacobsen, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, P. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Diabetic Kidney Problems
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Preventing end stage renal disease in diabetic patients — genetic aspect (part I)

Peter Karl Jacobsen

Steno Diabetes Center, Gentofte, Denmark, pkjacobsen{at}dadlnet.dk

Diabetic nephropathy is a major cause of diabetes-related morbidity and mortality; however the clinical course of the disease and the renal prognosis is highly variable among individuals. The current review will discuss the genetic influence on the development of end stage renal disease (ESRD) in diabetic patients and potential improvements to the current treatment strategy to slow the loss of kidney function in these patients. In this first part, the growing evidence that glucose-induced activation of the intra-renal and systemic renin-angiotensin systems plays an essential role in processes leading to destruction of renal function is summarised. Genetic variations, especially the angiotensin-converting enzyme (ACE)/ID polymorphisms in the gene coding for ACE, are involved in activation of the renin-angiotensin system and seem to influence the clinical course of diabetic nephropathy during treatment with ACE inhibitors. In addition, this polymorphism may interact with other polymorphisms within the reninangiotensin system, leading to high risk of ESRD. As new genetic approaches and methods develop, further understanding of diabetic nephropathy will evolve and genotyping will help prevent ESRD in diabetic patients.

Key Words: diabetic nephropathy • progression • genetics • renin-angiotensin system • ACE/ID • pharmacogenetics

References

  • Powers AC Diabetes Mellitus. In: Braunwald E, Fauci AS, Isselbacher KJ et al., editors. Harrison Online. Isselbacher KJ et al., editors. Harrison Online. New York: The McGraw-Hill Companies, 2002.
  • Parving H-H., sterby R., Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The Kidney. Philadelphia: WB Saunders, 2000: 1731-73.
  • Parving H-H., Viberti GC, Keen H., Christiansen JS, Lassen NA Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983;32:943-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Porte D., Jr., Schwartz MW Diabetes complications: why is glucose potentially toxic? Science 1996;272:699-700.[Web of Science][Medline] [Order article via Infotrieve]
  • Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cooper ME Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brenner BM, Meyer TW, Hostetter TH Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Hostetter TH, Rennke HG, Brenner BM The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.[Free Full Text]
  • Fogo AB Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59:804-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med 1998;15:900-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hovind P., Rossing P., Tarnow L., Smidt UM, Parving H-H. Progression of diabetic nephropathy. Kidney Int 2001;59:702-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jacobsen P., Tarnow L., Carstensen B., Hovind P., Poirier O., Parving H-H. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:2843-50.[Abstract/Free Full Text]
  • Bjorck S., Mulec H., Johnsen SA, Norden G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992;304:339-43.[Web of Science][Medline] [Order article via Infotrieve]
  • Kasiske BL, Kalil RS, Ma JZ, Liao M., Keane WF Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
  • Bilous RW Baseline and change in proteinuria and the risk of renal functional loss in the Irbesartan Diabetic Nephropathy Trial (IDNT). Diabet Med 2003;20(suppl 2):1-33.[Web of Science][Medline] [Order article via Infotrieve]
  • Ruggenenti P., Perna A., Remuzzi G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003;63:2254-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Zeeuw D., Remuzzi G., Parving H-H et al. Proteinuria reduction during antihypertensive therapy predicts renal and cardio-vascular protection in patients with Type 2 diabetic nephropathy. Diabetologia 2003;46(supplement 2):A339.[CrossRef]
  • De Jong PE, Navis G., De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mogensen CE Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982;285:685-8.[Medline] [Order article via Infotrieve]
  • Parving H-H., Andersen AR, Smidt UM, Svendsen PA Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1: 1175-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Parving H-H., Jacobsen P., Rossing K., Smidt UM, Hommel E., Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996;49:1778-82.[Web of Science][Medline] [Order article via Infotrieve]
  • Rossing P., Hougaard P., Borch-Johnsen K., Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Br Med J 1996;313:779-84.[Abstract/Free Full Text]
  • Raij L., Chiou XC, Owens R., Wrigley B. Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am J Med 1985;79:37-41.[Web of Science][Medline] [Order article via Infotrieve]
  • Anderson S., Rennke HG, Brenner BM Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.[Web of Science][Medline] [Order article via Infotrieve]
  • Anderson S., Rennke HG, Garcia DL, Brenner BM Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526-36.[Web of Science][Medline] [Order article via Infotrieve]
  • Taguma Y., Kitamoto Y., Futaki G.et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313:1617-20.[Abstract]
  • Parving H-H., Hommel E., Smidt UM Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297:1086-91.[Abstract/Free Full Text]
  • Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Viberti G., Mogensen CE, Groop LC, Pauls JF Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-9.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Parving H-H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
  • Giatras I., Lau J., Levey AS Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127:337-45.[Abstract/Free Full Text]
  • Jafar TH, Schmid CH, Landa M. et al.Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.[Abstract/Free Full Text]
  • Zatz R., Dunn BR, Meyer TW, Anderson S., Rennke HG, Brenner BM Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.[Web of Science][Medline] [Order article via Infotrieve]
  • Fogo A., Yoshida Y., Glick AD, Homma T., Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988;82:322-30.[Web of Science][Medline] [Order article via Infotrieve]
  • Bohrer MP, Deen WM, Robertson CR, Brenner BM Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 1977;233:F13-F21.[Web of Science][Medline] [Order article via Infotrieve]
  • Lapinski R., Perico N., Remuzzi A., Sangalli F., Benigni A., Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653-60.[Abstract]
  • Leehey DJ, SinghAK,Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:S93-S98. 41. Rincon-Choles H., Kasinath BS, Gorin Y., Abboud HE Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 2002;82:8-11.[Medline] [Order article via Infotrieve]
  • Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999;55:454-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15(suppl 6):61-3.[Free Full Text]
  • Burns KD Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36:449-67.[Web of Science][Medline] [Order article via Infotrieve]
  • Taal MW, Brenner BM Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zatz R., Brenner BM Pathogenesis of diabetic microangiopathy.The hemodynamic view. Am J Med 1986;80:443-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Osei SY, Price DA, Fisher ND, Porter L., Laffel LM, Hollenberg NK Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Hypertension 1999;33(1 Pt 2):559-64.[Abstract/Free Full Text]
  • Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36:122-6.[Abstract/Free Full Text]
  • Miller JA, Floras JS, Zinman B., Skorecki KL, LoganAG Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci (Lond) 1996;90: 189-95.[Medline] [Order article via Infotrieve]
  • Miller JA Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999;10:1778-85.[Abstract/Free Full Text]
  • Price DA, Porter LE, Gordon M. et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382-91.[Abstract/Free Full Text]
  • Imanishi M., Yoshioka K., Konishi Y. et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999;42:999-1005.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mizuiri S., Yoshikawa H., Tanegashima M. et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998;31:301-07.[Web of Science][Medline] [Order article via Infotrieve]
  • Christlieb AR, Kaldany A., D'Elia JA Plasma renin activity and hypertension in diabetes mellitus. Diabetes 1976;25:96974.
  • Perez GO, Lespier L., Jacobi J. et al. Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 1977;137:852-5.[Abstract/Free Full Text]
  • Wolf G., Ziyadeh FN The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.Am J Kidney Dis 1997;29:153-63.[Web of Science][Medline] [Order article via Infotrieve]
  • Hommel E., Mathiesen ER, Giese J., Nielsen MD, Schutten HJ, Parving H-H. On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy. Scand J Clin Lab Invest 1989;49:537-44.[Web of Science][Medline] [Order article via Infotrieve]
  • Deinum J.,Tarnow L., van Gool JM et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant 1999;14:1904-11.[Abstract/Free Full Text]
  • O'Hara JA, Ferriss JB,Twomey BM, Gonggrijp H., O'Sullivan DJ Changes in blood pressure, body fluids, circulating angiotensin II and aldosterone, with improved diabetic control. Clinical Science 1982;63:415s-418s.
  • Lieberman J., Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med 1980; 93:825-6.[Abstract/Free Full Text]
  • Marre M., Bernadet P., Gallois Y. et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384-8.[Abstract]
  • Tarnow L., Cambien F., Rossing P. et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995;44:489-94.[Abstract]
  • Florey CV, Uppal S., Lowy C. Relation between blood pressure, weight, and plasma sugar and serum insulin levels in schoolchildren aged 9-12 years in Westland, Holland. Br Med J 1976;1:1368-71.[Abstract/Free Full Text]
  • Jarrett RJ, Keen H., McCartney M. et al. Glucose tolerance and blood pressure in two population samples: their relation to diabetes mellitus and hypertension.IntJEpidemiol 1978;7:15-24.[Abstract/Free Full Text]
  • Mathiesen ER, Hilsted J., Feldt-Rasmussen B., Bonde-Petersen F., Christensen NJ, Parving H-H. The effect of metabolic control on hemodynamics in short-term insulin-dependent diabetic patients. Diabetes 1985;34:1301-05.[Abstract]
  • Parving H-H., Noer I., Deckert T. et al. The effect of metabolic regulation on microvascular permeability to small and large molecules in short-term juvenile diabetics. Diabetologia 1976;12:161-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marfella R., Nappo F., De Angelis L., Paolisso G., Tagliamonte MR, Giugliano D. Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care 2000;23:658-63. 68. Jacobsen P., Rossing K., Hansen BV, Bie P., Vaag A., Parving H-H. Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients. J Intern Med 2003;254:464-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kastrup J., Rorsgaard S., Parving H-H., Lassen NA Impaired autoregulation of cerebral blood flow in long-term type I (insulin-dependent) diabetic patients with nephropathy and retinopathy. Clin Physiol 1986;6:549-59.[Web of Science][Medline] [Order article via Infotrieve]
  • Kastrup J., Norgaard T., Parving H-H., Henriksen O., Lassen NA Impaired autoregulation of blood flow in subcutaneous tissue of long-term type 1 (insulin-dependent) diabetic patients with microangiopathy: an index of arteriolar dysfunction. Diabetologia 1985;28:711-17.[Web of Science][Medline] [Order article via Infotrieve]
  • Parving H-H., Kastrup H., Smidt UM, Andersen AR, Feldt-Rasmussen B., Christiansen JS Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1984;27:547-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Christensen PK, Hansen HP, Parving H-H. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997;52:1369-74.[Web of Science][Medline] [Order article via Infotrieve]
  • Seaquist ER, Goetz FC, Rich S., Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-5.[Abstract]
  • Schelling JR, Zarif L., Sehgal A., Iyengar S., Sedor JR Genetic susceptibility to end-stage renal disease. Curr Opin Nephrol Hypertens 1999;8:465-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tarnow L. Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors. Dan Med Bull 2002;49:19-42.[Web of Science][Medline] [Order article via Infotrieve]
  • Krolewski AS Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 1999;55:1582-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wang PH, Lau J., Chalmers TC Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.Lancet 1993;341:1306-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329: 977-86.[Abstract/Free Full Text]
  • Lander ES, Linton LM, Birren B. et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Venter JC,Adams MD, Myers EW et al.The sequence of the human genome. Science 2001;291:1304-51.[Abstract/Free Full Text]
  • Gambaro G., Anglani F., D'Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet 2000; 355:308-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Freely associating. Nat Genet 1999;22:1-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001;19:1-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.[Web of Science][Medline] [Order article via Infotrieve]
  • HunleyTE, Julian BA, Phillips JA, III et al.Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996;49:571-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Mizuiri S., Hemmi H., Kumanomidou H. et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int 2001;60:1124-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Staessen JA, Wang JG, Ginocchio G. et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997;15:1579-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fujisawa T., Ikegami H., Kawaguchi Y. et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998;41:47-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tarnow L., Gluud C., Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998;13: 1125-30.[Free Full Text]
  • Rudberg S., Rasmussen LM, Bangstad HJ, Osterby R. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000; 23:544-8.[Abstract]
  • SoliniA, DallaVM, SallerA., Nosadini R., Crepaldi G., Fioretto P. The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 2002;51:251-5.[Medline] [Order article via Infotrieve]
  • Harden PN, Geddes C., Rowe PA et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995;345:1540-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yoshida H., Mitarai T., KawamuraT. et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Parving H-H., Jacobsen P., Tarnow L. et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Br Med J 1996;313:591-4.[Abstract/Free Full Text]
  • Jacobsen P., Rossing K., Rossing P. et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53:1002-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Penno G., Chaturvedi N., Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998;47:1507-11.[Abstract/Free Full Text]
  • Parving H-H., Hommel E., Mathiesen E. et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988;296:156-60.[Medline] [Order article via Infotrieve]
  • Jacobsen P., Rossing K.,Tarnow L. et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999;71:S101-S105.[CrossRef][Medline] [Order article via Infotrieve]
  • Bjorck S., Blohme G., Sylven C., Mulec H. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 1997;12(suppl 2):67-70.[Abstract/Free Full Text]
  • Hadjadj S., Belloum R., Bouhanick B. et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 2001;12:541-9.[Abstract/Free Full Text]
  • Gumprecht J., Zychma MJ, Grzeszczak W., ZukowskaSzczechowska E. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int 2000;58:513-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fava S., Azzopardi J., Ellard S., Hattersley AT ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care 2001;24: 2115-20.[Abstract/Free Full Text]
  • Tomino Y., Makita Y., Shike T. et al. Relationship between polymorphism in the angiotensinogen, angiotensin- converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 1999;82:139-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yoshida H., Kuriyama S.,Atsumi Y. et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996;50:657-64.[Web of Science][Medline] [Order article via Infotrieve]
  • Marre M., Jeunemaitre X., Gallois Y. et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997;99:1585-95.[Web of Science][Medline] [Order article via Infotrieve]
  • Schmidt S., Strojek K., Grzeszczak W., Bergis K., Ritz E. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 1997;12:427-9.[Abstract/Free Full Text]
  • Kimura H., Gejyo F., Suzuki Y., Suzuki S., Miyazaki R.,Arakawa M. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy-1. Kidney Int 1998;54:1659-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vleming LJ, van der Pijl JW et al.The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 1999;51:133-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Wong TY, Chan JC, Poon E., Li PK Lack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235T gene polymorphism with renal function among Chinese patients with type II diabetes. Am J Kidney Dis 1999; 33:1064-70.[Medline] [Order article via Infotrieve]
  • Lovati E., Richard A., Frey BM, Frey FJ, Ferrari P. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 2001;60:46-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ha SK, Park HC, Park HS et al. ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: Effect of ACE gene DD on the progression of diabetic nephropathy. Am J Kidney Dis 2003;41:943-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Taal MW Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant? Curr Opin Nephrol Hypertens 2000;9:651-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schena FP, D'Altri C., Cerullo G., Manno C., Gesualdo L. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int 2001;60:732-40. 114. Greene T., Lau J., Levey AS Immunological Renal Diseases. CouserWG, 1997.
  • Levey AS, Greene T., Beck GJ et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999;10:2426-39.[Abstract/Free Full Text]
  • Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64. 117. van der Kleij FG, Schmidt A., Navis GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl 1998;53(suppl 63):S23-S26.
  • van der Kleij FG, De Jong PE, Henning RH, De Zeeuw D., Navis G. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002;13: 1025-33.[Abstract/Free Full Text]
  • Jackson B., Johnston CI Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension. Clin Exp Pharmacol Physiol 1984;11:355-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Andersen S., Tarnow L., Cambien F. et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002;62:192-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Andersen S., Tarnow L., Cambien F. et al. Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE insertion/deletion genotype? Diabetes Care 2003;26:1501-06.[Abstract/Free Full Text]
  • Keavney B., McKenzie CA, Connell JM et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet 1998;7:1745-51.[Abstract/Free Full Text]
  • Walker WG, Whelton PK, Saito H., Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1979;1:287-91.[Abstract/Free Full Text]
  • Jeunemaitre X., Soubrier F., Kotelevtsev YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Inoue I., NakajimaT, Williams CS et al.A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99:1786-97.[Web of Science][Medline] [Order article via Infotrieve]
  • Hopkins PN, Lifton RP, Hollenberg NK et al. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 1996;14:199-207.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Paillard F., Chansel D., Brand E. et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999;34:423-9.[Abstract/Free Full Text]
  • Rotimi C., Morrison L., Cooper R. et al. Angiotensinogen gene in human hypertension. Lack of an association of the 235T allele among African Americans. Hypertension 1994;24: 591-4.[Abstract/Free Full Text]
  • Hingorani AD, Jia H., Stevens PA, Hopper R., Dickerson JE, Brown MJ Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-09.[Web of Science][Medline] [Order article via Infotrieve]
  • de Gasparo M., Catt KJ, Inagami T., Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.[Abstract/Free Full Text]
  • BonnardeauxA, Davies E.,Jeunemaitre X. et al.Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension.Hypertension 1994;24:63-9.[Abstract/Free Full Text]
  • Miller JA, Thai K., Scholey JW Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56:2173-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miller JA, Thai K., Scholey JW Angiotensin II type 1 receptor gene polymorphism and the response to hyperglycemia in early type 1 diabetes. Diabetes 2000:49:1585-9.[Abstract]
  • Duncan JA, Scholey JW, Miller JA Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr Opin Nephrol Hypertens 2001;10:111-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frimat L., Philippe C., Maghakian MN et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men. J Am Soc Nephrol 2000;11:2062-7.[Abstract/Free Full Text]
  • Guttmacher AE, Collins FS Genomic medicine--a primer. N Engl J Med 2002;347:1512-20.[Free Full Text]
  • Cadman PE, O'Connor DT Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003;12:61-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Evans WE, McLeod HL Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl JMed 2003;348:538-49.[Free Full Text]
  • Savage DB,Agostini M., Barroso I. et al. Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 2002;31:379-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pei Y., Scholey J.,Thai K., Suzuki M., Cattran D. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997;100:814-20.[Web of Science][Medline] [Order article via Infotrieve]
  • Bantis C., Ivens K., Kreusser W. et al. Influence of Genetic Polymorphisms in the Renin Angiotensin System on IgA Nephropathy. J Am Soc Nephrol 2001;12[(abstract)]:91A.[CrossRef]
  • Kurland L., Melhus H., Karlsson J. et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.JHypertens 2002;20:657-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yip J., Mattock MB, Morocutti A., Sethi M., Trevisan R., Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993;342:883-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Cosmo S., Bacci S., Piras GP et al. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 1997;40:1191-6.[CrossRef][Medline] [Order article via Infotrieve]
  • Reaven GM Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.[Abstract]
  • Maddux BA, Sbraccia P., Kumakura S. et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus.Nature 1995;373:448-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frittitta L., Youngren J., Vigneri R., Maddux BA, Trischitta V., Goldfine ID PC-1 content in skeletal muscle of non-obese, nondiabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia 1996;39:1190-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Frittitta L.,Youngren JF, Sbraccia P. et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia 1997;40:282-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frittitta L., Spampinato D., Solini A. et al. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 1998;47:1095-100.[Abstract]
  • Maddux BA, Goldfine ID Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 2000;49:13-19.[Abstract]
  • Pizzuti A., Frittitta L., Argiolas A. et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999; 48:1881-4.[Abstract]
  • Gu HF, Almgren P., Lindholm E. et al. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes 2000;49: 1601-03.[Abstract]
  • Costanzo BV, Trischitta V., Di Paola R. et al. The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes 2001;50:831-6.[Abstract/Free Full Text]
  • Rasmussen SK, Urhammer SA, Pizzuti A. et al. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes 2000;49:1608-11.[Abstract]
  • De Cosmo S.,Argiolas A., Miscio G. et al.A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria. Diabetes 2000;49:521-4.[Abstract]
  • De Cosmo S., Miscio G., Zucaro L. et al.The role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progression. Nephrol Dial Transplant 2002;17:1402-07.[Abstract/Free Full Text]
  • Jacobsen P., Grarup N.,Tarnow L., Parving H-H., Pedersen O. PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. Nephrol Dial Transplant 2002;17:1408-12.[Abstract/Free Full Text]
  • Canani LH, Ng DP, Smiles A., Rogus JJ, Warram JH, Krolewski AS Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes 2002;51:1188-93.[Abstract/Free Full Text]
  • Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 2001;16(suppl 1):60-2.[Abstract/Free Full Text]
  • Huang PL, Huang Z., Mashimo H. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JA Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharmacol Sci 2001;22: 361-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Imperatore G., Hanson RL, Pettitt DJ, Kobes S., Bennett PH, Knowler WC Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998;47:821-30.[Abstract]
  • Zanchi A., Moczulski DK, Hanna LS, Wantman M., Warram JH, Krolewski AS Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000;57:405-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Noiri E., Satoh H., Taguchi J. et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002;40:535-40.[Abstract/Free Full Text]
  • Border WA, Yamamoto T., Noble NA Transforming growth factor beta in diabetic nephropathy. Diabetes Metab Rev 1996; 12:309-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yamaguchi Y., Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990;346:281-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sakharova OV, Taal MW, Brenner BM Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens 2001;10:727-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Cosmo S.,Tassi V.,Thomas S. et al.The Decorin gene 179 allelic variant is associated with a slower progression of renal disease in patients with type 1 diabetes. Nephron 2002;92:72-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Barlassina C., Schork NJ, Manunta P. et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000; 57:1083-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nicod J., Frey BM, Frey FJ, Ferrari P. Role of the alpha-adducin genotype on renal disease progression. Kidney Int 2002;61:1270-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wang JG, Staessen JA,Tizzoni L. et al. Renal function in relation to three candidate genes. Am J Kidney Dis 2001;38:1158-68.[Web of Science][Medline] [Order article via Infotrieve]
  • Narita I., Saito N., Goto S. et al. Role of uteroglobin G38A polymorphism in the progression of IgA nephropathy in Japanese patients. Kidney Int 2002;61:1853-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Neugarten J.,AcharyaA, Silbiger SR Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000;11:319-29.[Abstract/Free Full Text]
  • Seliger SL, Davis C., Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001; 10:219-25.[Web of Science][Medline] [Order article via Infotrieve]
  • Neugarten J. Gender and the progression of renal disease. J Am Soc Nephrol 2002;13:2807-09.[Free Full Text]
  • Hodgkinson AD, Sondergaard KL, Yang B., Cross DF, Millward BA, Demaine AG Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy. Kidney Int 2001;60:211-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakajima H., Takenaka M., Kaimori JY et al. Gene expression profile of renal proximal tubules regulated by proteinuria. Kidney Int 2002;61:1577-87.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • van de Vijver MJ, He YD et al.A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 1, 1-14 (2005)
DOI: 10.3317/jraas.2005.001
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. Nikzamir, A. Esteghamati, M. Feghhi, M. Nakhjavani, A. Rashidi, and Javad Zavar Reza
The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 109 - 114.
[Abstract] [PDF]

Home page
 CJASNHome page
P. Ruggenenti, P. Bettinaglio, F. Pinares, and G. Remuzzi
Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1511 - 1525.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Nikzamir, M. Nakhjavani, A. Esteghamati, and A. Rashidi
Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1274 - 1277.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jacobsen, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, P. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Diabetic Kidney Problems
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement